LncRNA HOXA-AS2 represses endothelium inflammation by regulating the activity of NF-κB signaling

Endothelium inflammation, which can lead to endothelial activation and dysfunction, is widely accepted as the major event in multiple vascular disorders. The lncRNA HOXA-AS2 was previously reported to be involved in multiple inflammation-linked cancers. However, the role of HOXA-AS2 in endothelium i...

Full description

Saved in:
Bibliographic Details
Published inAtherosclerosis Vol. 281; pp. 38 - 46
Main Authors Zhu, Xinxing, Liu, Yanli, Yu, Jinjin, Du, Jiang, Guo, Rui, Feng, Yanyan, Zhong, Genshen, Jiang, Yizhou, Lin, Juntang
Format Journal Article
LanguageEnglish
Published Ireland Elsevier B.V 01.02.2019
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Endothelium inflammation, which can lead to endothelial activation and dysfunction, is widely accepted as the major event in multiple vascular disorders. The lncRNA HOXA-AS2 was previously reported to be involved in multiple inflammation-linked cancers. However, the role of HOXA-AS2 in endothelium inflammation is poorly understood. This study aims to determine the regulatory role of HOXA-AS2 in endothelium inflammation and related vascular diseases. High throughput mRNA sequencing was performed to establish expression profiles after HOXA-AS2 depletion. We extracted total RNAs of human peripheral blood mononuclear cells from normal control group and experimental group with carotid artery atherosclerosis, and performed qRT-PCR to assay the correlation between HOXA-AS2 expression and inflammatory vascular diseases. Inhibition of HOXA-AS2 can induce the activation of NF-κB signaling and subsequent inflammatory response. More importantly, HOXA-AS2 is inversely found to be inversely regulated by NF-κB in a negative feedback manner by helping recruit BRD4/P-TEFb complex to HOXA-AS2 promoter region, therefore facilitating release of the promoter-proximal paused RNA polymerase II and activating transcription elongation. We identify HOXA-AS2 as a critical repressor of endothelium inflammation. Moreover, this study offers us a new way to balance the NF-κB signaling-driven excessive endothelium inflammation by establishing a NF-κB/HOXA-AS2 negative feedback loop. Based on these findings, we conclude that HOXA-AS2 may serve as a crucial therapeutic target for various vascular disorders which are significantly associated with endothelium inflammation. [Display omitted] •We identify lncRNA HOXA-AS2 as a critical repressor of endothelium inflammation.•HOXA-AS2 has a significant correlation with carotid artery atherosclerosis.•HOXA-AS2 represses the activation of NF-κB signaling by controlling IκBα degradation and RelA acetylation at K310 site.•NF-κB inversely activates the transcription elongation of HOXA-AS2 by establishing a NF-κB/HOXA-AS2 negative feedback loop.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0021-9150
1879-1484
1879-1484
DOI:10.1016/j.atherosclerosis.2018.12.012